Shan Liu, SM; Lauren E. Cipriano, BSc, BA; Mark Holodniy, MD; Douglas K. Owens, MD, MS; Jeremy D. Goldhaber-Fiebert, PhD
Chronic hepatitis C virus is difficult to treat and affects approximately 3 million Americans. Protease inhibitors increase the effectiveness of standard therapy, but they are costly. A genetic assay may identify patients most likely to benefit from this treatment advance.
To assess the cost-effectiveness of new protease inhibitors and an interleukin (IL)–28B genotyping assay for treating chronic hepatitis C virus.
Decision-analytic Markov model.
Published literature and expert opinion.
Treatment-naive patients with chronic, genotype 1 hepatitis C virus monoinfection.
Strategies are defined by the use of IL-28B genotyping and type of treatment (standard therapy [pegylated interferon with ribavirin]; triple therapy [standard therapy and a protease inhibitor]). Interleukin-28B–guided triple therapy stratifies patients with CC genotypes to standard therapy and those with non-CC types to triple therapy.
Discounted costs (in 2010 U.S. dollars) and quality-adjusted life-years (QALYs); incremental cost-effectiveness ratios.
For patients with mild and advanced fibrosis, universal triple therapy reduced the lifetime risk for hepatocellular carcinoma by 38% and 28%, respectively, and increased quality-adjusted life expectancy by 3% and 8%, respectively, compared with standard therapy. Gains from IL-28B–guided triple therapy were smaller. If the protease inhibitor costs $1100 per week, universal triple therapy costs $102 600 per QALY (mild fibrosis) or $51 500 per QALY (advanced fibrosis) compared with IL-28B–guided triple therapy and $70 100 per QALY (mild fibrosis) and $36 300 per QALY (advanced fibrosis) compared with standard therapy.
Results were sensitive to the cost of protease inhibitors and treatment adherence rates.
Data on the long-term comparative effectiveness of the new protease inhibitors are lacking.
Both universal triple therapy and IL-28B–guided triple therapy are cost-effective when the least-expensive protease inhibitor are used for patients with advanced fibrosis.
Shan Liu, Lauren E. Cipriano, Mark Holodniy, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert. New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis. Ann Intern Med. 2012;156:279–290. doi: 10.7326/0003-4819-156-4-201202210-00005
Download citation file:
Published: Ann Intern Med. 2012;156(4):279-290.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use